AD diagnosis is based on clinical symptom evaluation, cognitive testing and brain imaging and, in some cases, supported by the molecular diagnostics, namely the monitoring of the gold standard biomarker triplet (Aβ, total-Tau and P-Tau 181) in the cerebrospinal fluid (CSF) [6, 7]. The gene discussed is MAPT; the disease is Alzheimer disease.